Related Experiment Video
Updated: Jul 15, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System
Michelle A Fravel1, Calvin J Meaney2, Lama Noureddine3
1University of Iowa College of Pharmacy, 167 CPB, 180 S. Grand Ave, Iowa City, IA, 52242, USA. michelle-fravel@uiowa.edu.
Insights
Managing hyperkalemia in chronic kidney disease (CKD) patients on renin-angiotensin-aldosterone system (RAAS) inhibitors requires prioritizing strategies that maintain RAAS inhibitor therapy. This approach preserves kidney and cardiovascular protection, crucial for patient outcomes.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Renin-angiotensin-aldosterone system (RAAS) inhibitors are vital for cardiovascular disease and kidney function in chronic kidney disease (CKD) patients.
- Hyperkalemia, a risk factor for arrhythmias and mortality, is a common complication of RAAS inhibitor use in CKD.
- Discontinuing RAAS inhibitors due to hyperkalemia can negate their protective benefits.
Purpose of the Study:
- To outline critical management principles for hyperkalemia in CKD patients on RAAS inhibitors.
- To emphasize strategies that allow for the continuation of RAAS inhibitor therapy.
- To balance the risks of hyperkalemia with the benefits of RAAS inhibition.
Main Methods:
- Prioritize hyperkalemia mitigation strategies that do not interfere with RAAS inhibitor therapy.
- Discontinue non-RAAS inhibitor medications causing hyperkalemia.
- Correct metabolic acidosis and maximize potassium-lowering medications like diuretics and SGLT-2 inhibitors.
- Consider potassium exchange resins for sustained RAAS inhibitor use.
- Employ concurrent strategies for effective hyperkalemia management.
Main Results:
- Concurrent application of multiple strategies is key to mitigating hyperkalemia and maintaining RAAS inhibitor therapy.
- Persistence of RAAS inhibitor use slows kidney function decline and prevents adverse cardiovascular events.
- A deliberate approach to reduce serum potassium allows for continuation of maximally dosed RAAS inhibitors.
- Patient education and engagement are vital for successful potassium management.
Conclusions:
- Effective hyperkalemia management in CKD patients on RAAS inhibitors is essential for preserving renal and cardiovascular protection.
- A multi-faceted approach, including lifestyle and medication adjustments, enables sustained RAAS inhibitor therapy.
- Maintaining RAAS inhibitor therapy is crucial for long-term patient outcomes in CKD.
Purpose Of Review:
Use of renin-angiotensin-aldosterone system (RAAS) inhibiting medications is critical in the prevention of cardiovascular disease and kidney function decline in patients with chronic kidney disease (CKD); however, these agents can lead to hyperkalemia, an electrolyte disorder associated with risk of arrythmia, conduction disorders, and increased overall mortality. Discontinuation, or reduction of dose, of RAAS inhibitor therapy in hyperkalemic patients with CKD can lead to loss of kidney and cardiovascular protection afforded by these medications. Given the high prevalence of hyperkalemia among patients with CKD utilizing RAAS inhibitors, clear management principles are critical to minimize risk and maximize benefit when facing this clinical dilemma.
Recent Findings:
Strategies to mitigate hyperkalemia that do not interfere with optimal RAAS inhibitor therapy should be prioritized when managing potassium elevation in patients with CKD. These strategies include discontinuing non-RAAS inhibitor medications known to cause hyperkalemia, correction of metabolic acidosis, and maximization of medication therapies that lower serum potassium, including diuretics and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Initiation of potassium exchange resins should also be considered to allow for sustained RAAS inhibitor utilization. An approach which employs multiple strategies concurrently is important to mitigate hyperkalemia and maintain long-term use of RAAS-inhibitors. Persistence of RAAS inhibitor use in patients with CKD is important to slow kidney function decline, delay onset of dialysis or the need for kidney transplant, and prevent adverse cardiovascular outcomes. When hyperkalemia develops among patients with CKD utilizing a RAAS inhibitor, a deliberate effort to reduce serum potassium levels using an approach that allows for continuation of maximally dosed RAAS inhibitor therapy is important. Patient education and engagement in the potassium management process is important for sustained success.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Chronic Kidney Disease III: Interprofessional Care
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Antihypertensive Drugs: Potassium-Sparing Diuretics

